favipiravir for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 all comers meta-analysis
NCT04310228-FAVI (Zhao) ChiCTR2000030894		RCT	favipiravir	tocilizumab	COVID 19 all comers	some concern	-/-	inconclusive	inconclusive 68 % decrease in radiologic improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Cai -FAVIPIRAVIR ChiCTR2000029600		NRa	favipiravir	interferon	COVID 19 all comers	NA	35/45	uncontrolled	[uncontrolled] Chest CT improvement (day 14): 91.4% (32/35)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 all comers meta-analysis